{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:08:24Z","timestamp":1793102904422,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.survophthal.2019.06.001","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T18:52:42Z","timestamp":1561056762000},"page":"770-779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":121,"title":["Critical review: Typical and atypical optic neuritis"],"prefix":"10.1016","volume":"64","author":[{"given":"Anne","family":"Abel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collin","family":"McClelland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.survophthal.2019.06.001_bib1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.survophthal.2019.06.001_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jocn.2017.10.030","article-title":"Paraneoplastic neuromyelitis optica spectrum disorder: A case report and review of the literature","volume":"48","author":"Annus","year":"2018","journal-title":"J\u00a0Clin Neurosci"},{"issue":"2","key":"10.1016\/j.survophthal.2019.06.001_bib3","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3988\/jcn.2018.14.2.246","article-title":"Paraneoplastic neuromyelitis optica associated with lung adenocarcinoma in a young woman","volume":"14","author":"Baik","year":"2018","journal-title":"J\u00a0Clin Neurol"},{"issue":"1","key":"10.1016\/j.survophthal.2019.06.001_bib4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/1352458511421185","article-title":"Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy","volume":"18","author":"Barnett","year":"2012","journal-title":"Mult Scler"},{"issue":"9","key":"10.1016\/j.survophthal.2019.06.001_bib5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A\u00a0randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group","volume":"326","author":"Beck","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.survophthal.2019.06.001_bib6","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJM199312093292403","article-title":"The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group","volume":"329","author":"Beck","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.survophthal.2019.06.001_bib7","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0161-6420(94)31103-1","article-title":"The course of visual recovery after optic neuritis. Experience of the optic neuritis treatment trial","volume":"101","author":"Beck","year":"1994","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.survophthal.2019.06.001_bib8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/WNO.0000000000000508","article-title":"Neuromyelitis optica: Deciphering a complex immune-mediated astrocytopathy","volume":"37","author":"Bennett","year":"2017","journal-title":"J\u00a0Neuroophthalmol"},{"key":"10.1016\/j.survophthal.2019.06.001_bib9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.msard.2018.08.008","article-title":"Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis","volume":"25","author":"Bensi","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.survophthal.2019.06.001_bib10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/WNO.0000000000000328","article-title":"Primary central nervous system vasculitis with optic nerve involvement","volume":"36","author":"Benson","year":"2016","journal-title":"J\u00a0Neuroophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2019.06.001_bib11","first-page":"2173","article-title":"Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France","volume":"264","author":"Biotti","year":"2017","journal-title":"J\u00a0Neurol"},{"issue":"4","key":"10.1016\/j.survophthal.2019.06.001_bib12","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.survophthal.2019.06.001_bib13","first-page":"917","article-title":"Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study","volume":"265","author":"Cabre","year":"2018","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.survophthal.2019.06.001_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.msard.2017.11.004","article-title":"Frequency of brain MRI abnormalities in neuromyelitis optica spectrum disorder at presentation: A cohort of Latin American patients","volume":"19","author":"Carnero Contentti","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.survophthal.2019.06.001_bib15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG)-positive optic neuritis: Clinical characteristics, radiologic clues and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2019.06.001_bib16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamaophthalmol.2017.6757","article-title":"Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the optic neuritis treatment trial","volume":"136","author":"Chen","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2019.06.001_bib17","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1177\/0961203316683265","article-title":"Neuro-ophthalmologic manifestations in systemic lupus erythematosus","volume":"26","author":"de Andrade","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.survophthal.2019.06.001_bib18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jneuroim.2018.01.003","article-title":"A\u00a0case of paraneoplastic neuromyelitis optica associated with small cell lung carcinoma","volume":"316","author":"Deuel","year":"2018","journal-title":"J\u00a0Neuroimmunol"},{"issue":"3","key":"10.1016\/j.survophthal.2019.06.001_bib19","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1474-4422(15)00393-2","article-title":"MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines","volume":"15","author":"Filippi","year":"2016","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.survophthal.2019.06.001_bib20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1474-4422(17)30469-6","article-title":"Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: A retrospective study","volume":"17","author":"Filippi","year":"2018","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.survophthal.2019.06.001_bib21","first-page":"CD001430","article-title":"Corticosteroids for treating optic neuritis","author":"Gal","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.survophthal.2019.06.001_bib22","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1212\/WNL.0000000000006189","article-title":"Optic neuritis in the diagnosis of MS: More than meets the eye","volume":"91","author":"Gass","year":"2018","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.survophthal.2019.06.001_bib23","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/archopht.1991.01080120057025","article-title":"The clinical profile of optic neuritis. Experience of the optic neuritis treatment trial","volume":"109","year":"1991","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2019.06.001_bib24","first-page":"727","article-title":"Multiple sclerosis risk after optic neuritis: Final optic neuritis treatment trial follow-up","volume":"65","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.survophthal.2019.06.001_bib25","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jns.2018.01.042","article-title":"Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in patients with optic neuritis and seizures","volume":"387","author":"Gutman","year":"2018","journal-title":"J\u00a0Neurol Sci"},{"issue":"10","key":"10.1016\/j.survophthal.2019.06.001_bib26","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1212\/WNL.0b013e31826845fe","article-title":"Does natalizumab therapy worsen neuromyelitis optica?","volume":"79","author":"Jacob","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.survophthal.2019.06.001_bib27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J\u00a0Neuroinflammation"},{"issue":"1","key":"10.1016\/j.survophthal.2019.06.001_bib28","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J\u00a0Neuroinflammation"},{"issue":"1","key":"10.1016\/j.survophthal.2019.06.001_bib29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J\u00a0Neuroinflammation"},{"issue":"10","key":"10.1016\/j.survophthal.2019.06.001_bib30","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ophtha.2018.03.041","article-title":"Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis","volume":"125","author":"Jitprapaikulsan","year":"2018","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2019.06.001_bib31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/01658107.2017.1335333","article-title":"Atypical optic neuritis after inactivated influenza vaccination","volume":"42","author":"Jun","year":"2018","journal-title":"Neuroophthalmology"},{"issue":"11","key":"10.1016\/j.survophthal.2019.06.001_bib32","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1212\/WNL.54.11.2039","article-title":"Practice parameter: The role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"54","author":"Kaufman","year":"2000","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.survophthal.2019.06.001_bib33","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis optica spectrum disorder: An international update","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.survophthal.2019.06.001_bib34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1016\/j.survophthal.2019.06.001_bib35","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/1352458515598020","article-title":"Retinal ganglion cell layer thinning within one month of\u00a0presentation for optic neuritis","volume":"22","author":"Kupersmith","year":"2016","journal-title":"Mult Scler"},{"issue":"9997","key":"10.1016\/j.survophthal.2019.06.001_bib36","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0140-6736(15)61137-0","article-title":"Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): A randomised, controlled, double-blind, non-inferiority trial","volume":"386","author":"Le Page","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.survophthal.2019.06.001_bib37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1752-1947-8-155","article-title":"Neuromyelitis optica presenting with relapses under treatment with natalizumab: A case report","volume":"8","author":"Lee","year":"2014","journal-title":"J\u00a0Med Case Rep"},{"issue":"1","key":"10.1016\/j.survophthal.2019.06.001_bib38","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s12974-018-1335-x","article-title":"Chronic relapsing inflammatory optic neuropathy (CRION): A manifestation of myelin oligodendrocyte glycoprotein antibodies","volume":"15","author":"Lee","year":"2018","journal-title":"J\u00a0Neuroinflammation"},{"issue":"9451","key":"10.1016\/j.survophthal.2019.06.001_bib39","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A\u00a0serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.survophthal.2019.06.001_bib40","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/WNO.0000000000000509","article-title":"Advances in neuromyelitis optica: Take them to the clinic","volume":"37","author":"Levin","year":"2017","journal-title":"J\u00a0Neuroophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2019.06.001_bib41","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1080\/03009740701218832","article-title":"Retrobulbar optic neuritis revealing primary anti-phospholipid antibody syndrome","volume":"36","author":"Marie","year":"2007","journal-title":"Scand J Rheumatol"},{"issue":"22","key":"10.1016\/j.survophthal.2019.06.001_bib42","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1212\/WNL.0b013e3181c3fd5b","article-title":"A\u00a0short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS","volume":"73","author":"Martinelli","year":"2009","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.survophthal.2019.06.001_bib43","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1212\/WNL.0b013e3182887957","article-title":"Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution","volume":"80","author":"Matthews","year":"2013","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.survophthal.2019.06.001_bib44","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/WNO.0b013e31825e8e2e","article-title":"Optic perineuritis as the presenting feature of Crohn disease","volume":"32","author":"McClelland","year":"2012","journal-title":"J\u00a0Neuroophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2019.06.001_bib45","doi-asserted-by":"crossref","first-page":"E790","DOI":"10.1097\/OPX.0b013e3181f361b0","article-title":"Ocular perineuritis secondary to neurosyphilis","volume":"87","author":"Meehan","year":"2010","journal-title":"Optom Vis Sci"},{"issue":"3","key":"10.1016\/j.survophthal.2019.06.001_bib46","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1177\/1352458507084107","article-title":"Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome","volume":"14","author":"Mehta","year":"2008","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.survophthal.2019.06.001_bib47","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.survophthal.2019.06.001_bib48","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1212\/01.WNL.0000138572.82125.F5","article-title":"The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis","volume":"63","author":"Morrow","year":"2004","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.survophthal.2019.06.001_bib49","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jamaneurol.2018.0024","article-title":"Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: A randomized clinical trial","volume":"75","author":"Morrow","year":"2018","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.survophthal.2019.06.001_bib50","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.3129\/i09-145","article-title":"Optic neuritis as an initial presentation of Wegener's granulomatosis","volume":"44","author":"Moubayed","year":"2009","journal-title":"Can J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2019.06.001_bib51","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/WNL.0b013e3181aaea32","article-title":"Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis","volume":"73","author":"Naismith","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.survophthal.2019.06.001_bib52","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.msard.2017.07.023","article-title":"A\u00a0case of MOG antibody-positive bilateral optic neuritis and meningoganglionitis following a genital herpes simplex virus infection","volume":"17","author":"Nakamura","year":"2017","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.survophthal.2019.06.001_bib53","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12883-018-1165-6","article-title":"Visual outcome is similar in optic neuritis patients treated with oral and i.v. high-dose methylprednisolone: A retrospective study on 56 patients","volume":"18","author":"Naumovska","year":"2018","journal-title":"BMC Neurol"},{"issue":"1","key":"10.1016\/j.survophthal.2019.06.001_bib54","first-page":"191","article-title":"Bilateral ocular perineuritis as the presenting feature of acute syphilis infection","volume":"259","author":"O'Connell","year":"2012","journal-title":"J\u00a0Neurol"},{"issue":"6","key":"10.1016\/j.survophthal.2019.06.001_bib55","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1212\/WNL.50.6.1833","article-title":"Randomized trial comparing two different high doses of methylprednisolone in\u00a0MS: A clinical and MRI study","volume":"50","author":"Oliveri","year":"1998","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.survophthal.2019.06.001_bib56","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon Beta treatment in neuromyelitis optica: Increase in relapses and aquaporin 4 antibody titers","volume":"67","author":"Palace","year":"2010","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.survophthal.2019.06.001_bib57","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/1352458506070732","article-title":"Immunosuppressive therapy is more effective than interferon in neuromyelitis optica","volume":"13","author":"Papeix","year":"2007","journal-title":"Mult Scler"},{"key":"10.1016\/j.survophthal.2019.06.001_bib58","first-page":"621872","article-title":"Neurosyphilis presenting as asymptomatic optic perineuritis","volume":"2012","author":"Parker","year":"2012","journal-title":"Case Rep Ophthalmol Med"},{"issue":"1-2","key":"10.1016\/j.survophthal.2019.06.001_bib59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jns.2015.05.034","article-title":"Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: A review","volume":"355","author":"Pereira","year":"2015","journal-title":"J\u00a0Neurol Sci"},{"issue":"7","key":"10.1016\/j.survophthal.2019.06.001_bib60","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1468-1331.2008.02146.x","article-title":"Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis","volume":"15","author":"Perumal","year":"2008","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.survophthal.2019.06.001_bib61","first-page":"17","article-title":"Chronic relapsing inflammatory optic neuropathy: A systematic review of 122 cases reported","volume":"261","author":"Petzold","year":"2014","journal-title":"J\u00a0Neurol"},{"issue":"7","key":"10.1016\/j.survophthal.2019.06.001_bib62","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archneur.63.7.964","article-title":"Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch Neurol"},{"issue":"9","key":"10.1016\/j.survophthal.2019.06.001_bib63","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1001\/archopht.119.9.1299","article-title":"Optic perineuritis: Clinical and radiographic features","volume":"119","author":"Purvin","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2019.06.001_bib64","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1442-9071.2009.02122.x","article-title":"Optic perineuritis secondary to Wegener's granulomatosis","volume":"37","author":"Purvin","year":"2009","journal-title":"Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2019.06.001_bib65","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1212\/NXI.0000000000000040","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis","volume":"1","author":"Ramanathan","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.survophthal.2019.06.001_bib66","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.survophthal.2019.06.001_bib67","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1212\/WNL.52.7.1479","article-title":"A\u00a0randomized, controlled trial of oral high-dose methylprednislone in acute optic neuritis","volume":"52","author":"Sellebjerg","year":"1999","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.survophthal.2019.06.001_bib68","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1177\/1352458517731914","article-title":"Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies","volume":"24","author":"Sep\u00falveda","year":"2018","journal-title":"Mult Scler"},{"key":"10.1016\/j.survophthal.2019.06.001_bib69","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.msard.2018.11.008","article-title":"Autoimmune diseases associated with neuromyelitis optica spectrum disorders: A literature review","volume":"27","author":"Shahmohammadi","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"16","key":"10.1016\/j.survophthal.2019.06.001_bib70","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/WNL.0b013e3181f8832e","article-title":"IFN\u03b2-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum","volume":"75","author":"Shimizu","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.survophthal.2019.06.001_bib71","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.msard.2018.01.010","article-title":"Beneficial effect of plasma exchange in acute attack of neuromyelitis optica spectrum disorders","volume":"20","author":"Srisupa-Olan","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"44","key":"10.1016\/j.survophthal.2019.06.001_bib72","doi-asserted-by":"crossref","first-page":"e5194","DOI":"10.1097\/MD.0000000000005194","article-title":"Optic neuritis as an initial presentation of primary Sj\u00f6gren syndrome: A case report and literature review","volume":"95","author":"Sun","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.survophthal.2019.06.001_bib73","first-page":"888","article-title":"Primary Sj\u00f6gren's syndrome related optic neuritis","volume":"6","author":"Tang","year":"2013","journal-title":"Int J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2019.06.001_bib74","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.survophthal.2019.06.001_bib75","first-page":"1","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J\u00a0Neurol"},{"issue":"3","key":"10.1016\/j.survophthal.2019.06.001_bib76","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/cen3.12107","article-title":"Evaluation of aquaporin-4 antibody assays","volume":"5","author":"Waters","year":"2014","journal-title":"Clin Exp Neuroimmunol"},{"issue":"10","key":"10.1016\/j.survophthal.2019.06.001_bib77","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.survophthal.2019.06.001_bib78","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1352458511431077","article-title":"The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease","volume":"18","author":"Wingerchuk","year":"2012","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.survophthal.2019.06.001_bib79","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.survophthal.2019.06.001_bib80","doi-asserted-by":"crossref","first-page":"e527","DOI":"10.1212\/WNL.0000000000006873","article-title":"Optical coherence tomography is highly sensitive in detecting prior optic neuritis","volume":"92","author":"Xu","year":"2019","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.survophthal.2019.06.001_bib81","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1442-9071.2007.01539.x","article-title":"Optic perineuritis as a rare initial presentation of sarcoidosis","volume":"35","author":"Yu-Wai-Man","year":"2007","journal-title":"Clin Exp Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2019.06.001_bib82","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1136\/bjophthalmol-2017-311177","article-title":"Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients","volume":"102","author":"Zhao","year":"2018","journal-title":"Br J Ophthalmol"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625719300414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625719300414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:48:39Z","timestamp":1758541719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625719300414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":82,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0039625719300414"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2019.06.001","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Critical review: Typical and atypical optic neuritis","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2019.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}